Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 3;192(Supplement_1):i3-i14.
doi: 10.1093/bjd/ljae238.

Unravelling the complex pathogenesis of hidradenitis suppurativa

Affiliations
Review

Unravelling the complex pathogenesis of hidradenitis suppurativa

John W Frew. Br J Dermatol. .

Abstract

Hidradenitis suppurativa (HS) is a complex inflammatory disease, with rapid advances being made in our understanding of the complex immunological pathogenesis of the condition. New insights into the genomic landscape of HS have identified a number of genes that contribute to the development of HS in a polygenic manner, contributing to inflammatory dysregulation and alterations in epidermal stem cell fate in the follicular unit. These genomic variations can explain unique aspects of the disease such as the development and presence of epithelialized tunnels and abnormalities in wound healing. From genetic and translational studies, it is likely that these genetic alterations predispose to an innate immune dysregulation that can be triggered through sex hormone-responsive transcription factors with hormonal changes such as puberty, pregnancy and the menstrual cycle. The role of sex hormones in HS also has direct effects upon the development and maturation of inflammatory cells such as monocytes, which has the potential to explain differential patient response to treatments such as interleukin-23 antagonism. The role of adipose tissue as an active immunological organ also plays a role in the immune dysregulation seen in the disease. Fibrotic tissue and immunologically active fibroblasts play a significant role in the perpetuation of inflammation and development of adaptive immune dysfunction in the disease. The cutaneous and gut microbiomes play significant roles in the activation of innate immunity, although conflicting data exist as to their central or peripheral role in disease pathogenesis. Overall, our understanding of disease pathogenesis in HS is moving toward a more nuanced, complex paradigm in which patient heterogeneity in presentation and immunological characteristics are moving closer to the identification of therapeutic biomarkers to guide therapeutic modalities in the management of this burdensome condition.

Plain language summary

Hidradenitis suppurativa (HS) is a chronic disease that can have a negative impact on a person’s quality of life. To improve treatment for HS, we need to understand how the disease works. A lot of research has focused on the cells and chemical messengers that circulate in the skin and the body, and how these interact to cause HS. Recent genetic studies have found that certain genes associated with inflammation can be passed down through families and cause HS. These genes may become more active with specific hormones present in the body, explaining why HS often appears around puberty and can vary with hormonal changes. The genes affect hair follicle growth, increase inflammation and are involved in tunnel growth (hollow connections underneath the skin). The type of inflammation involved in HS is complex and many different types of cells are involved, including those that have previously been seen as less important. Other things like body fat, hormones and bacteria on the skin and in the gut can alter some of these cells and the chemicals they produce. However, in some cases it is unclear whether these changes impact the skin or not. The more we learn about how HS works, the better we can find and make medications to treat it. Scientists are also working on identifying people who will get HS at an early stage and deciding on the best treatments with tests called biomarkers.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: J.W.F. has conducted advisory work for Janssen, Boehringer Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, ChemoCentryx, AbbVie and UCB; has participated in trials for Pfizer, UCB, Boehringer Ingelheim, Eli Lilly, CSL, Janssen and AbbVie; and has received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, Janssen and La Roche Posay.

MeSH terms

Substances

LinkOut - more resources